Progress, challenges and global approaches to rare diseases.

Area of Science:

• Medical research
• Genetics
• Public health

Background:

• Rare diseases affect all life stages, imposing significant psychosocial and economic burdens on patients and families.
• While diagnostic and therapeutic efforts have advanced for some of the estimated 7000 rare diseases, 90% still lack effective treatments.
• Definitions vary globally, with the US defining rare diseases as affecting fewer than 200,000 people, and the EU defining them as affecting fewer than 1 in 2000 people.

Purpose of the Study:

• To highlight the unmet medical and social needs of rare disease patients.
• To emphasize the need for expanded awareness, advocacy, and outreach, particularly in underserved populations.
• To discuss the role of patient-research partnerships and technological advancements in rare disease therapy development.

Main Methods:

• Review of current rare disease definitions and statistics.
• Analysis of challenges in diagnosis and treatment development.
• Exploration of emerging technologies like bioinformatics, artificial intelligence (AI), and machine learning (ML) in rare disease research.

Main Results:

• Significant progress has been made in understanding and treating some rare diseases, but a vast majority remain untreated.
• Patient involvement in research and regulatory initiatives are accelerating therapeutic development.
• AI, ML, and big data analytics are proving instrumental in identifying novel therapeutics, predicting disease patterns, and optimizing patient care.

Conclusions:

• Expanded awareness, advocacy, and equitable outreach are crucial for addressing the global burden of rare diseases.
• Patient-centered research and regulatory support are vital for advancing the pipeline of new therapies.
• Technological innovations in bioinformatics and AI hold immense promise for discovering and evaluating treatments for rare diseases, offering hope to millions worldwide.